e-learning
resources
Milan 2017
Monday, 11.09.2017
Bronchodilators and bronchoprotectors
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical synergism of LABA/LAMA combinations in COPD patients
P. Rogliani (Roma, Rm, Italy)
Source:
International Congress 2017 – Bronchodilators and bronchoprotectors
Session:
Bronchodilators and bronchoprotectors
Session type:
Poster Discussion
Number:
1814
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Rogliani (Roma, Rm, Italy). Clinical synergism of LABA/LAMA combinations in COPD patients. 1814
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
Source: Eur Respir Rev 2017; 26: 160043
Year: 2017
Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Lack of clinically relevant differences between combination therapy and monotherapy in COPD
Source: Eur Respir J 2014; 43: 1204-1205
Year: 2014
Lack of clinically relevant differences between combination therapy and monotherapy in COPD
Source: Eur Respir J 2014; 43: 1204
Year: 2014
Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept